Express News | Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Vertex Pharmaceuticals Initiated With a Sector Perform at Scotiabank
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Vertex Pharmaceuticals Price Target Lowered to $541 From $550 at BofA
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474
Vertex Pharmaceuticals (VRTX) Receives a Hold From Morgan Stanley
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
Raymond James Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals Reinstated With a Market Perform at Raymond James
Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst ...
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Today's Analyst Rating | Meta Platforms Price Target Raised to $655 by KeyBanc, T-Mobile US Price Target Raised to $215 by Barclays
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Brookdale Senior Living (BKD) and Vertex Pharmaceuticals (VRTX)
Express News | Vertex Pharmaceuticals Inc : RBC Raises Target Price to $437 From $425